Background As known, miocarditis often matched the progression of chronic heart failure (CHF) in patients with connective tissue disease. Meldonium have shown miocardial cytoprotection effect, however the role of meldonium in patients with connective tissue disease remains debatable.
Objectives We aimed to evaluate the effects of meldonium for CHF after miocarditis in patients with connective tissue disease.
Methods 40 patients (9 M, 31 F, mean age – 37,20±4,46 years) with connective tissue disease and CHF NYHA I-III class after miocarditis were enrolled. 20 (50%) patients received the standard treatment and meldonium 500 mg/day (study group), while 20 (50%) (control group) – received only the standard treatment for 12 weeks. Echocardiographic parameters, 6 min walk test and quality-of-life scores (QoL) were performed in all patients at baseline and at the end of the study.
Results Echocardiographic parameters, 6 min walk test distance and QoL scores did not differ significantly between the groups, with the exception of a more favourable emotional score in the study group (P =0.027). After 12 weeks of treatment with meldonium the incidence of exertion-related symptoms, including chest pain, dyspnoea, and fatigue were significantly lower in the study in comparison of control groups (P=0.05). The distance of the 6 min walk test in 30% patients have been increased in the study group by 26,47% (d<0,01); in control group in 19% patients – by 9,47% (d<0,01). 6 min walk test correlated to NYHA functional class (r =0,25; d<0,05).
Conclusions Meldonium is effective and safe for patients with CHF after miocarditis in patients with connective tissue disease. Meldonium reduces progression of CHF after miocarditis in patients with connective tissue disease. Its administration may provide benefits for the reduction of hospitalizations and mortality in its population.
Disclosure of Interest None Declared